RxDoctor Payments Data

Sucheta Gosavi, MD

Hospitalist · El Paso, TXNPI 1114025061

Payments from drug & device makers

$1,202in general payments, 2019–2025

Across 46 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$201
  • Sanofi-aventis U.S. LLC$154
  • Merck$153
  • Novo Nordisk$116
  • Cvrx, Inc.$104
  • Novartis$73
  • plus $401 from 13 others

What the payments were for

  • Food & beverage$1,08690%
  • Education$11610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,202 in reported general payments places this provider in the 90th percentile of 1,284 hospitalist providers in Texas.

See all hospitalist providers in Texas

Medicare billing

Part B allowed, 2024
$260,236
Medicare patients
999
Services billed
3,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban491$639,596
XareltoRivaroxaban84$109,901
Repatha SureclickEvolocumab73$90,111
EntrestoSacubitril/Valsartan58$72,259
Praluent PenAlirocumab49$50,058
JardianceEmpagliflozin43$44,120
NexletolBempedoic Acid18$14,606
Metoprolol Succinate1,034$12,740
Atorvastatin Calcium1,120$9,213
Losartan Potassium850$7,739
NexlizetBempedoic Acid/Ezetimibe11$7,167
Ezetimibe242$4,881
Carvedilol498$4,095
Rosuvastatin Calcium322$4,073
Amlodipine Besylate654$3,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$639,596491 claims
NovartisEntresto$73$72,25958 claims
Boehringer IngelheimJardiance$23$44,12043 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$69$21,77329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 hospitalist providers in Texas.

Other hospitalist in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →